Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Reports Third Quarter 2019 Financial Results
Gimoti NDA resubmission on track for fourth quarter 2019 SOLANA BEACH, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third
View HTML
Toggle Summary Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™
SOLANA BEACH, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches of its product candidate Gimoti
View HTML
Toggle Summary Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results
NDA resubmission anticipated in fourth quarter 2019 SOLANA BEACH, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that following receipt of U.S.
View HTML
Toggle Summary Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA
SOLANA BEACH, Calif. , June 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted a type A meeting request and meeting package to the U.S.
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2019 Financial Results
Projected cash runway extended to first quarter 2020 SOLANA BEACH, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter
View HTML
Toggle Summary Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA
SOLANA BEACH, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S.
View HTML
Toggle Summary Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA
Meeting with FDA scheduled for March 21, 2019 SOLANA BEACH, Calif. , March 14, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted its response to the U.S.
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication
Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration ( FDA ) for Gimoti™ 505(b)(2) New Drug Application (NDA) April 1 , 2019 Prescription Drug User Fee Act (PDUFA) date maintained Company expects to hold a conference call at a later date instead of its
View HTML
Toggle Summary Evoke Pharma Receives Preliminary FDA Communication on Gimoti™ NDA
SOLANA BEACH Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), today announced the receipt of a multi-disciplinary review (DR) letter from the U.S. Food and Drug Administration ( FDA ) in association with the Gimoti 505(b)(2) New Drug Application (NDA).
View HTML
Toggle Summary Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results
SOLANA BEACH, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company will release financial results for the fourth quarter and full year ended
View HTML